As leaders in cardiology, the physicians at Carient are committed to continuing their education and growing their understanding of the best practices and treatments. Often, this new knowledge comes about through clinical research, which is why our team at Carient is dedicated to conducting and participating in research protocols. The insights revealed through clinical research will enable our patients to obtain the newest treatments before they are available to the general public. Carient is one of the few sites in Northern Virginia that participates in large cardiovascular clinical trials that are otherwise only available to major academic centers.

Carient’s physicians are honored to participate in vital and impactful clinical research in the field of cardiology. This research ultimately leads to new advancements in the care we provide our patients. We have been one of only a few sites elected to participate in several elite research studies and new interventional devices and procedures.

The Clinical Research Institute at Carient was established in 2010 under the supervision of Dr. Hamid Taheri. We have participated in over 25 large clinical trials. Our patients have access to new treatments and we have been recognized nationally for our successful enrollment.

We are currently accepting new patients into the following studies:


The purpose of this study is to test the efficiency effect of the MK-1242 (vericiguat) compared with placebo, added to best usual treatment, on the risk of being admitted to hospital with worsening heart failure (HF) hospitalization in patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF).


The main purpose of the study is to determine the effectiveness of Empagliflozin vs. Placebo, added to best usual treatment, for patients with Chronic Heart Failure and preserved ejection fraction (HFpEF).


Evaluation of the Alere NT -proBNP for ARCHITECT Assay in an Outpatient Setting for Heart Failure.  Enrolling patients who visit a cardiologist’s office for evaluation of possible heart failure.


The purpose of this study is to evaluate the efficiency and safety of LCZ696 compared to Ramipril in addition to conventional post – AMI treatment, in reducing the occurrence of composite endpoint of CV death, HF hospitalization and outpatient HF (time-to-first event analysis) in post – AMI patients with evidence of LV systolic dysfunction and/or pulmonary congestion, with no known prior history of chronic HF.


Influenza infection is known to be associated with increased risk of cardiovascular (CV) events.  INVESTED is a large multicenter trial to access the cardiopulmonary benefit of high-dose compared with standard-dose influenza vaccine in a high-risk cardiovascular population.


Please contact us for more information or if you are interested in participating in a studies.  Your cardiologist can also speak to you more about being a candidate for a research study during your office visit.
703-335-8750 x-1173.